Assistant Professor, Pharmacology & Toxicology Department
Ph.D.- Western Michigan University, 2016
Dr. Michael Berquist’s research interests are to develop and evaluate adjunct pharmacotherapies for treating drug use disorders and mental health conditions, such as posttraumatic stress disorder. There is a renewed interest in the use of psychedelics and entactogens, such as 3,4-methylenedioxymethamphetamine (MDMA) for treating drug abuse and a variety of mental health conditions. Psychedelics and entactogens represent a unique class of putative medications for these clinical purposes as they seem to catalyze the effectiveness of psychotherapies and behavioral interventions that are used for treating drug use disorders and mental health conditions. Dr. Berquist primarily utilizes behavioral assays in rodents (including operant conditioning of food- or drug-maintained responding, locomotor activity and sensitization) to study the pharmacological effects of psychedelics and other treatments. Dr. Berquist is also collaborating with Dr. Eric Peterson to test the effectiveness of an adeno-associated virus (AAV) gene-based therapy for the treatment of methamphetamine abuse, and with Dr. Shengyu Mu to study the cardiovascular effects of various drugs of abuse.
- Berquist MD, Leth-Petersen S, Kristensen JL, Fantegrossi WE. In vivo effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in rodents: Drug discrimination and thermoregulation. Drug Alcohol Depend. 2020 Mar 1;208:107850. doi: 10.1016/j.drugalcdep.2020.107850. Epub 2020 Jan 13. PMID: 31954950.
- Berquist MD, Leth-Petersen S, Kristensen JL, Fantegrossi WE. Locomotor effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in mice: psychostimulant effects, stereotypy, and sensitization. Psychopharmacology (Berl). 2020 Feb;237(2):431-442. doi: 10.1007/s00213-019-05380-3. Epub 2019 Nov 15. PMID: 31729537.
- Bullock TA, Berquist MD, Baker LE. Locomotor sensitization in male Sprague-Dawley rats following repeated concurrent treatment with 4-methylmethcathinone and 3,4-methylenedioxymethamphetamine. Behav Pharmacol. 2019 Oct;30(7):566-573. doi: 10.1097/FBP.0000000000000491. PMID: 31268871.
- Hyatt WS, Berquist MD, Chitre NM, Russell LN, Rice KC, Murnane KS, Fantegrossi WE. Repeated administration of synthetic cathinone 3,4-methylenedioxypyrovalerone persistently increases impulsive choice in rats. Behav Pharmacol. 2019 Oct;30(7):555-565. doi: 10.1097/FBP.0000000000000492. PMID: 31211703.
- McClenahan SJ, Hambuchen MD, Simecka CM, Gunnell MG, Berquist MD, Owens SM. Cardiovascular effects of 3,4-methylenedioxypyrovalerone (MDPV) in male and female Sprague-Dawley rats. Drug Alcohol Depend. 2019 Feb 1;195:140-147. doi: 10.1016/j.drugalcdep.2018.12.006. Epub 2019 Jan 4. PubMed PMID: 30634109; PubMed Central PMCID: PMC6915966.
- Hambuchen MD, Berquist MD, Simecka CM, McGill MR, Gunnell MG, Hendrickson HP, Owens SM. Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats. J Pharm Pharm Sci. 2019;22(1):301-312. doi: 10.18433/jpps30471. PMID: 31329536.
- Berquist MD, Hyatt WS, Bauer-Erickson J, Gannon BM, Norwood AP, Fantegrossi WE. Phencyclidine-like in vivo effects of methoxetamine in mice and rats. Neuropharmacology. 2018 May 15;134(Pt A):158-166. doi: 10.1016/j.neuropharm.2017.08.028. Epub 2017 Aug 19. PMID: 28830759; PMCID: PMC5818319.
- Fantegrossi WE, Wilson CD, Berquist MD. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug Metab Rev. 2018 Feb;50(1):65-73. doi: 10.1080/03602532.2018.1428343. Epub 2018 Jan 31. Review. PMID: 29385930; Central PMCID: PMC6419500.
- Berquist MD, Fantegrossi WE. Discriminative Stimulus Effects of Psychostimulants. Curr Top Behav Neurosci. 2018;39:29-49. doi: 10.1007/7854_2017_5. Review. PubMed PMID: 28341944.
- Ford BM, Franks LN, Tai S, Fantegrossi WE, Stahl EL, Berquist MD, Cabanlong CV, Wilson CD, Penthala NR, Crooks PA, Prather PL. Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development. Pharmacol Res. 2017 Nov;125(Pt B):161-177. doi: 10.1016/j.phrs.2017.08.008. Epub 2017 Aug 23. PMID: 28838808; PMCID: PMC5849406.